

Francesca Girolami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1985036/publications.pdf>

Version: 2024-02-01

50
papers

3,297
citations

185998

28
h-index

182168

51
g-index

56
all docs

56
docs citations

56
times ranked

3687
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. <i>Heart Failure Clinics</i> , 2022, 18, 31-37.	1.0	12
2	Clinical Exome Sequencing Revealed a De Novo FLNC Mutation in a Child with Restrictive Cardiomyopathy. <i>Neurology International</i> , 2022, 12, 206-211.	0.2	1
3	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 1276-1286.	2.9	14
4	Hidden familial cardiomyopathies in children: Role of genetic testing. <i>International Journal of Cardiology</i> , 2021, 340, 55-58.	0.8	1
5	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. <i>Genetics in Medicine</i> , 2021, 23, 856-864.	1.1	45
6	The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2021, 18, 1-8.	1.0	1
7	Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, CIRCEP121010562.	2.1	6
8	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 300, 191-195.	0.8	60
9	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1821-1831.	0.8	15
10	Comprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome. <i>JACC: Case Reports</i> , 2020, 2, 925-929.	0.3	2
11	A rare case of pediatric cardiomyopathy: Alström syndrome identified by gene panel analysis. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3369-3373.	0.2	2
12	Clinical Profile of Cardiac Involvement in Danon Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e003117.	1.6	29
13	Mitochondrial Energetics and Ca ²⁺ -Activated ATPase in Obstructive Hypertrophic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1799.	1.0	4
14	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. <i>Journal of the American Heart Association</i> , 2020, 9, e015473.	1.6	42
15	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. <i>Genetics in Medicine</i> , 2019, 21, 284-292.	1.1	54
16	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. <i>Circulation</i> , 2019, 139, 830-833.	1.6	43
17	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. <i>JAMA Cardiology</i> , 2018, 3, 520.	3.0	78
18	Contemporary genetic testing in inherited cardiac disease. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 1-11.	0.6	48

#	ARTICLE	IF	CITATIONS
19	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. <i>European Journal of Heart Failure</i> , 2018, 20, 898-906.	2.9	54
20	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2018, 138, 1387-1398.	1.6	468
21	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. <i>Progress in Pediatric Cardiology</i> , 2018, 51, 24-30.	0.2	3
22	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 273, 155-161.	0.8	17
23	Incident Atrial Fibrillation Is Associated With <i>MYH7</i> Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e005191.	1.6	46
24	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	42
25	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 1151-1159.	0.7	25
26	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 16.	0.3	9
27	Genetic advances in sarcomeric cardiomyopathies: state of the art. <i>Cardiovascular Research</i> , 2015, 105, 397-408.	1.8	187
28	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 232-243.	1.1	14
29	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2015, 8, 1014-1021.	1.6	67
30	Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2589-2600.	1.2	118
31	Novel β -Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 741-750.	5.1	74
32	Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2014, 114, 769-776.	0.7	76
33	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2013, 112, 1190-1196.	0.7	34
34	Fulminant Multifocal Motor Neuropathy: A Report of Two Cases. <i>International Journal of Neuroscience</i> , 2012, 122, 395-400.	0.8	4
35	Molecular genetics made simple. <i>Global Cardiology Science & Practice</i> , 2012, 2012, 6.	0.3	6
36	Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations. <i>Journal of the American College of Cardiology</i> , 2011, 58, 839-848.	1.2	138

#	ARTICLE	IF	CITATIONS
37	Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation. <i>Neurology International</i> , 2011, 1, 3.	0.2	0
38	Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. <i>Europace</i> , 2010, 12, 347-355.	0.7	127
39	Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1444-1453.	1.2	256
40	Bioinformatics for Next Generation Sequencing Data. <i>Genes</i> , 2010, 1, 294-307.	1.0	65
41	Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 392-397.	1.1	7
42	The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 349-367.	1.1	65
43	The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. <i>Journal of Physiology</i> , 2008, 586, 3639-3644.	1.3	90
44	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2008, 83, 630-638.	1.4	198
45	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2008, 83, 630-638.	1.4	296
46	Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1043-1048.	1.2	208
47	A molecular screening strategy based on β -myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 601-607.	0.6	64
48	Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. <i>American Journal of Cardiology</i> , 2003, 92, 1358-1362.	0.7	43
49	Identification of seven novel mutations of F8C by DHPLC. <i>Human Mutation</i> , 2002, 20, 231-232.	1.1	21
50	Microsatellite analysis of chromosome 3p region in sporadic renal cell carcinomas. <i>Pathology and Oncology Research</i> , 2002, 8, 241-244.	0.9	10